Sector: MedicalAOB (NYSE: AOB)
Ranking History
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 132 |
Technical : | 230 |
Performance : | 283 |
Overall: | 261 |
Number of Stocks: | 306 |
Scan Date: | 10/20/2009 |
Sector: | Medical |
Funamental : | 132 |
Technical : | 241 |
Performance : | 281 |
Overall: | 268 |
Number of Stocks: | 305 |
Scan Date: | 10/15/2009 |
Sector: | Medical |
Funamental : | 135 |
Technical : | 235 |
Performance : | 280 |
Overall: | 263 |
Number of Stocks: | 305 |
Headlines
- Still Not Enough Hazardous Waste -- Keeping Watchful Eye
Nov 02, 2009 03:40 PM | AOB, EBAY, ECOL, JCOM
- China Aoxing Pharmaceutical Company to Present at 2009 China Growth Conference of Adam Friedman Associates on October 28, 2009
Oct 19, 2009 08:31 AM | AOB, CAXG
- China Aoxing Pharmaceutical Company to Present at 2009 Roth China Conference
Oct 06, 2009 08:03 AM | AOB, CAXG
- China Aoxing Pharmaceutical Company to Present at Maxim Group Third Annual Growth Conference
Sep 29, 2009 02:00 PM | AOB, CAXG
- China Aoxing Pharmaceutical Company Honorably Awarded Center of Excellence in Enterprise Technology by Consortium of China Government Offices
Sep 24, 2009 08:01 AM | AOB, CAXG
- asensio.com Announces Two New Research Report Publications on AOB
Sep 22, 2009 08:30 AM | AOB
- China Aoxing Pharmaceutical Company Receives SFDA Approval for Clinical Trial of Abuse Resistant Opioid Drug
Sep 17, 2009 08:01 AM | AOB, CAXG
- AOBO Launches New OTC Product to Treat Throat Inflammation
Sep 11, 2009 09:00 AM | AOB
- American Oriental Bioengineering Announces September Investor Conferences Participation
Sep 08, 2009 08:01 AM | AOB, MS
- China Aoxing Pharmaceutical Company Announces Submission of NDA of Its Leading Narcotic Drug for the Treatment of Acute Moderate to Severe Cough
Sep 03, 2009 08:02 AM | AOB, CAXG
- China Aoxing Pharmaceutical Company Reports Fiscal Year 2009 Financial Results
Oct 14, 2009 09:53 AM | AOB, CAXG
- Halter USX China Index Up 10.59% for Third Quarter 2009
Sep 30, 2009 05:51 PM | ABAT, ACH, ACTS, ADY, AMCN, AOB
- AOBO's Products Included in China's Essential Drug List
Aug 26, 2009 03:00 PM | AOB
- American Oriental Bioengineering's 'Jinji Capsules' and 'Boke Nasal Spray' Designated Among 'China's Top Branded Drugs of 2009'
Aug 18, 2009 11:59 AM | AOB
- American Oriental Bioengineering Announces Change in Independent Auditor
Aug 11, 2009 08:31 AM | AOB
- American Oriental Bioengineering Reports Second Quarter 2009 Financial Results
Aug 07, 2009 06:52 AM | AOB
- AOBO Announces New Product Launch
Aug 07, 2009 06:46 AM | AOB
- American Oriental Bioengineering to Report Second Quarter 2009 Financial Results on August 7, 2009
Jul 27, 2009 04:02 PM | AOB
- China Aoxing Pharmaceutical Company Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
Jul 23, 2009 08:01 AM | AOB, CAXG
- American Oriental Bioengineering Honorably Elected a Top 20 Most Competitive Public Pharmaceutical Company in China
Jul 21, 2009 09:00 AM | AOB
- Form 4 Zhang Boqing For: Mar 24 (10K)
Apr 01, 2009 01:38 PM
- Form 4 Patti Cosimo J For: Mar 24 (10K)
Apr 01, 2009 01:38 PM
- Form 4 Wizel Lawrence S For: Mar 24 (10K)
Apr 01, 2009 01:38 PM
- Form 4 Wang Xianmin For: Mar 24 (10K)
Apr 01, 2009 01:38 PM
- Form 4 LI BINSHENG For: Apr 20 (10K)
Feb 17, 2009 09:51 PM
- Form 5 LI BINSHENG For: Dec 31 (10K)
Feb 17, 2009 09:49 PM
- Form 4 AMERICAN ORIENTAL BIOENG For: Apr 20 Filed by: Liu Tony (10K)
Feb 17, 2009 09:49 PM
- Form 5 LI YANCHUN For: Dec 31 (10K)
Feb 17, 2009 09:49 PM
- Form 5 AMERICAN ORIENTAL BIOENG For: Dec 31 Filed by: Liu Tony (10K)
Feb 17, 2009 09:49 PM
- Form 4 LI YANCHUN For: Apr 20 (10K)
Feb 17, 2009 09:47 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
AOB
|
Compare to S&P
|
| YTD |
-41.68 %
|
-49.16 %
|
| 4 Weeks |
-15.92 %
|
-16.81 %
|
| 12 Weeks |
-23.55 %
|
-25.45 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 54.55 %
|
|
EPS Growth in Last Year: -5.56 %
|
|
Sales Growth in Last Quarter: 54.57 %
|
|
Sales Growth in Last Quarter: 20.69 %
|
|
